More from the RapidGen™ Platform
Preclinical Drug Discovery & Development with Alternative Models
InVivo Biosystems is a globally recognized leader in preclinical drug discovery and development using alternative animal models. Trusted by biotech and pharmaceutical companies worldwide, we deliver cost-effective, human-relevant solutions that transcend traditional test tube methods, providing deeper insights and accelerating innovation.
Determine if a lead compound ameliorates disease phenotypes or affect important metabolites.
Determine if genes are involved in disease processes and make good targets for further discovery.
Medium throughput screen of compound libraries and biologics (up to BSL2).
Perform acute embryo toxicity testing, targeted hepatotoxicity, neurotoxicity, and cardiotoxiciity analysis.
We perform lifetime monitoring of a large animal population to determine whether compounds and formulations affect lifespan and health span. Get data, including Kaplan-Meier survival estimates and detailed lifespan activity, in just 2-3 months.
We assess compounds against Reactive Oxygen Species (ROS) damage. Through proprietary ROS exposure assays, get insights into a compound’s antioxidant efficacy in 2-3 months.
We utilize RNAseq technology to analyze a compound’s effects on gene expression, offering insights beneficial for human clinical studies. Choose from Data Only, Interpretation, or Customization packages. Turnaround: 2-3 months.
We investigate the compound’s effect on mitochondrial health during aging using fluorescent imaging. Obtain raw images, statistics, and analyses over a 2-3 month timeframe.
We offer an innovative Gut Microbiome Study using zebrafish and C. elegans models, focusing on large-scale, cost-effective, and translatable research. Gain in-depth insights into microbial roles and genetic pathways in just 2-3 months, perfect for product development and patenting.
1. Why are zebrafish models vital for Preclinical Studies in Drug Discovery?
Zebrafish are essential in preclinical studies as they share genetic similarities with humans and have a rapid reproductive cycle. They are an ideal animal model in the drug development process for observing drug effects, potential side effects, and efficacy in the early stages of drug discovery. This integration can streamline the preclinical development and boost the drug candidate’s journey toward clinical trials.
2. How can a Contract Research Organization specializing in zebrafish enhance Preclinical Services?
A Contract Research Organization (CRO) offering zebrafish services enhances preclinical services by providing rapid, cost-effective, and high-quality data from preclinical testing. Leveraging zebrafish for preclinical trials ensures a thorough examination of the drug candidate, aligning with regulatory requirements and assisting in smooth transitions to clinical development.
3. What role do zebrafish play in Preclinical Testing for Medical Devices and Drug Development?
In preclinical testing for medical devices and drug development, zebrafish models provide insights into the biocompatibility and safety of new medical technologies and potential drug candidates. Their use helps in ensuring that the products meet the regulatory standards, thus smoothing the pathway to clinical studies and eventually to the market.
4. What is the significance of zebrafish in studying Drug Development and Preclinical Contract in Clinical Trials?
Zebrafish services offer an innovative approach for preclinical contracts in clinical trials. These animal models expedite the drug development program by enhancing the study design, ensuring regulatory submissions align with the expectations of regulatory authorities, and providing high-quality preclinical safety testing data.
5. How do Zebrafish models aid in the Drug Development Industries and Biopharmaceutical Companies?
Biopharmaceutical companies leverage zebrafish models for efficient and reliable preclinical studies, ensuring their development phase produces robust, high-quality results for a successful transition to clinical phases.
Ready to get started?
Ready to connect with us to learn more about working with our company or our technology?
Submit your inquiry below & we will get back to you soon.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.